Amgen stock: buy or sell?

AMGN stock price: $199.08 -2.13% At close on August 23rd, 2019

Updated on:
August 23rd, 2019

5

Shares of Amgen eased an awful -2.13% and closed at $199.08.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

Should I buy Amgen stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Amgen stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Amgen stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we gathered 15 ratings published for AMGN stock in the last 30 days.

The general sentiment of these ratings is bullish for AMGN stock, with 9 positive ratings.
Is AMGN a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-21Royal Bank of Canadan/aSector Perform
2019-8-19MizuhoBuyNeutral
2019-8-16Credit Suisse Groupn/aOutperform
2019-8-13Oppenheimern/aOutperform
2019-8-12Wells Fargo & CoMarket PerformPositive
2019-7-15Morgan Stanleyn/aOverweight
2019-7-1Mizuhon/aBuy
2019-6-24Mizuhon/aBuy
2019-5-21Royal Bank of Canadan/aNeutral
2019-5-15JPMorgan Chase & Co.n/aHold
2019-4-1Cantor Fitzgeraldn/aHold
2019-3-22Mizuhon/aBuy
2019-3-14BMO Capital Marketsn/aOutperform
2019-2-26Cowenn/aBuy
2019-2-13Mizuhon/aBuy

Amgen stock analysis

Daily outlook

Amgen shares eased -2.13% to $199.08 today.

Amgen shares eased -2.13% to $199.08 today. On Aug 8th AMGN price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. For the last 14 days when SMA50d and SMA100d crossed up, AMGN price gained $15.15 per share (8.24%). On Aug 13th, AMGN hit a new all time high, pushing higher than on August 12th tops. Check different trading setups that use ATHs as triggers.

AMGN stock chart (daily)

Weekly outlook

Amgen shares fell -2.42% this week, ending at $199.08. Late July AMGN rocketed an extraordinary 6.34% in just one week. Early July AMGN plunged a chilling -6.29% in just one week.

Not so far away is the last price record Amgen marked last week. Amgen stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

AMGN stock chart (weekly)

Amgen stock price history

Amgen IPO was on June 17th, 1983 at $0.29 per share1. Since then, AMGN stock grew a 68,548.30%, with an average of 1,904.10% per year. If you had invested right after AMGN's IPO a $1,000 in Amgen stock in 1983, it would worth $685,483.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Amgen stock historical price chart

AMGN stock reached all-time highs on Aug 13th with a price of $210.41.

Amgen stock price target is $209.90

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 13 price targets for AMGN stock released in the last month:
AMGN stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-21Royal Bank of CanadaRaises Targetn/a$192.00-
2019-8-19MizuhoDowngrades$208.00$212.001.9%
2019-8-16Credit Suisse GroupReiterates$202.00$225.0011.4%
2019-8-13OppenheimerRaises Target$210.00$230.009.5%
2019-8-12Wells Fargo & CoReiterates$197.00$202.002.5%
2019-7-15Morgan StanleyLowers Target$211.00$207.00-1.9%
2019-7-1MizuhoReiteratesn/a$208.00-
2019-6-24MizuhoReiteratesn/a$208.00-
2019-5-21Royal Bank of CanadaSet Price Targetn/a$192.00-
2019-5-15JPMorgan Chase & Co.Reiteratesn/a$190.00-
2019-4-1Cantor FitzgeraldReiteratesn/a$221.00-
2019-3-22MizuhoSet Price Targetn/a$208.00-
2019-2-26CowenReiteratesn/a$234.00-
(in average)$205.60$209.902.0%
The price forecast for Amgen stock is $209.90, moving in a range between $234.00 and $190.00.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on April, Amgen climbed an impressive 14.66%. Unfortunately, reported EPS is not yet available in our database.
AMGN earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a2.91n/a
2017-Q32017-10-253.113.275.1%
2017-Q42018-02-013.032.89-4.6%
2018-Q12018-04-243.233.477.4%
2018-Q22018-07-263.523.838.8%
2018-Q32018-10-303.423.697.9%
2018-Q42019-01-293.263.424.9%
2019-Q12019-04-223.48n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, Amgen annual revenues gained a beatiful 3.93% to $23,747.00 million USD from $22,849.00 marked in 2017. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) climbed a 26.69% to 35.35%.

Amgen fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amgen TTM sales up to March 2019 were $23,750.00 and income $8,075.00 million dollars. If we compare this TTM figures with the last reported annuality, we can review Amgen business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, stayed steady a tight 0.01%. Regarding profit margin, Amgen declined -1.35% to 35.35%

AMGN annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$18,670 M-$5,080 M27.2%-
2014$20,063 M7.46%$5,158 M25.7%1.54%
2015$21,662 M7.97%$6,939 M32.0%34.53%
2016$22,991 M6.14%$7,722 M33.6%11.28%
2017$22,849 M-0.62%$1,979 M8.7%-74.37%
2018$23,747 M3.93%$8,394 M35.3%324.15%
TTM $23,750 M0.01%$8,075 M34.0%-3.80%

Quarterly financial results

Amgen posted $5,557.00 M in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 million with a profit margin of 35.85%. Profit margin appreciated a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing revenues to same quarter last year, Amgen sales marked a neutral move and remained constant a 0.05%.
AMGN quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$5,780 M-$2,150 M37.2%-
2017-Q3$5,780 M0.00%$2,020 M34.9%-6.05%
2017-Q4$5,802 M0.38%$-4,264 M-73.5%-311.09%
2018-Q1$5,554 M-4.27%$2,311 M41.6%-154.20%
2018-Q2$6,059 M9.09%$2,296 M37.9%-0.65%
2018-Q3$5,904 M-2.56%$1,859 M31.5%-19.03%
2018-Q4$6,230 M5.52%$1,928 M30.9%3.71%
2019-Q1$5,557 M-10.80%$1,992 M35.8%3.32%

Amgen ownership

When you are planning to invest in shares of a stock, it's worth to overview its ownership structure.

Amgen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.21% of all shares.

Bearish positions for AMGN stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Amgen:

AMGNABBVALXNBIIBBMY
Market cap$121.4 B$99.9 B$27.7 B$45.0 B$78.0 B
Total shares609.9 M1,480.0 M224.3 M193.9 M1,630.0 M
Float shares598.3 M1,480.0 M223.6 M184.0 M1,630.0 M
  - Institutional holdings (%)81.9%71.9%96.8%93.4%75.0%
  - Insider holdings (%)0.2%0.1%0.3%0.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Amgen summary

Friday, August 23rd, 2019
Open$203.09
Close$199.08
Day range$198.01 - $203.62
Previous close$203.42
Session gain-2.13%
Average true range$6.14
50d mov avg$184.84
100d mov avg$180.19
200d mov avg$184.01
Daily patternlt01a
Weekly pattern lt06a

Amgen performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Amgen to AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer:
Stock3m6m12m
AMGNAmgen17.05%7.85%4.36%
ABBVAbbVie-14.38%-13.20%-27.04%
ALXNAlexion Pharmaceu...-2.79%-4.81%5.10%
BIIBBiogen2.20%-28.67%-32.21%
BMYBristol-Myers Squ...3.15%-4.45%-17.61%
CELGCelgene0.49%7.37%6.43%
GILDGilead Sciences-3.08%-0.43%-9.60%
GSKGlaxoSmithKline3.70%3.99%4.92%
JNJ-5.46%-2.60%-0.86%
PFEPfizer-15.59%-16.85%-14.36%

Amgen competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Amgen. We picked 9 companies as Amgen competitors as they are in the same industry or have similar market objectives.

Latest Amgen stock news